Trifluridine

Pre-clinicalCompleted

1 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Mycobacterium Avium-Intracellulare Infection

Conditions

Mycobacterium Avium-Intracellulare Infection, HIV Infections

Trial Timeline

— → —

NCT ID

NCT00002037

About Trifluridine

Trifluridine is a pre-clinical stage product being developed by Amgen for Mycobacterium Avium-Intracellulare Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT00002037. Target conditions include Mycobacterium Avium-Intracellulare Infection, HIV Infections.

What happened to similar drugs?

3 of 8 similar drugs in Mycobacterium Avium-Intracellulare Infection were approved

Approved (3) Terminated (1) Active (4)

✅clarithromycin, rifabutinPfizerApproved

✅AzithromycinPfizerApproved

✅Azithromycin + Rifabutin/rifampinPfizerApproved

🔄Ethambutol hydrochloride + Clarithromycin + AzithromycinPfizerPhase 3

🔄ALIS + Azithromycin + Ethambutol + ELCInsmedPhase 3

🔄ALIS + Azithromycin + Ethambutol + ELC (matching placebo for ALIS)InsmedPhase 3

🔄LAI (Liposomal Amikacin for Inhalation) 590 mgInsmedPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00002037	Pre-clinical	Completed	—	—	Mycobacterium Avium-Intracellulare Infection

Competing Products

20 competing products in Mycobacterium Avium-Intracellulare Infection

See all competitors

Product	Company	Stage	Hype Score
clarithromycin, rifabutin	Pfizer	Approved	43
Azithromycin	Pfizer	Pre-clinical	26
Ethambutol hydrochloride + Clarithromycin + Azithromycin	Pfizer	Phase 3	40
Azithromycin	Pfizer	Pre-clinical	26
Azithromycin	Pfizer	Pre-clinical	26
Azithromycin	Pfizer	Pre-clinical	26
Azithromycin	Pfizer	Approved	43
Tigecycline	Pfizer	Phase 2	35
Azithromycin + Rifabutin/rifampin	Pfizer	Approved	43
ALIS + Azithromycin + Ethambutol + ELC	Insmed	Phase 3	37
ALIS + Azithromycin + Ethambutol + ELC (matching placebo for ALIS)	Insmed	Phase 3	37
LAI plus multi-drug regimen	Insmed	Phase 2	32
Liposomal amikacin for inhalation (LAI) + placebo	Insmed	Phase 2	32
LAI (Liposomal Amikacin for Inhalation) 590 mg	Insmed	Phase 3	37
Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours) + Ceftriaxone for Injection + Amoxicillin + Azithromcyin + clarithromycin + Clofazimine + Ethambutol + Amikacin Injection + tigecycline + Imipenem + Cilastatin + Cefoxitin + Amikacin (Inhalation) + linezolid + Trimethoprim / Sulfamethoxazole + Doxycycline + moxifloxacin + bedaquiline + Rifabutin	Innoviva	Phase 2	36
Molgramostim nebulizer solution	Savara	Phase 2	21
Inhaled molgramostim + Antimycobacterial regimen	Savara	Phase 2	29
Epetraborole + Epetraborole + Placebo + Placebo	AN2 Therapeutics	Phase 2	32
SPR720 + Placebo + Open-label Standard of Care	Spero Therapeutics	Phase 2	17
RHB-204 + Placebo	RedHill Biopharma	Phase 3	22